Today: 9 June 2026
UK stock market today: FTSE 100 slips as upbeat UK data meets rate-cut doubts; Babcock, C&C move
23 January 2026
2 mins read

UK stock market today: FTSE 100 slips as upbeat UK data meets rate-cut doubts; Babcock, C&C move

London, Jan 23, 2026, 10:57 GMT — Regular session

Britain’s FTSE 100 slipped on Friday, surrendering early gains after a streak of solid finishes as investors balanced stronger UK data against hints the Bank of England could hold off on rate cuts. The blue-chip index dropped 0.13% to 10,136.43, with the mid-cap FTSE 250 down 0.42% at 23,271.99.

The numbers carried weight, arriving just as markets wrestle with how fast the BoE might ease policy without sparking inflation again. UK stocks may seem sheltered—the FTSE 100 is heavy on global earners—but the interest rate narrative still seeps into banks, retailers, and housebuilders.

Retail sales delivered an early surprise. December’s volumes climbed 0.4%, according to the Office for National Statistics, defying predictions of a 0.1% drop and driven by online purchases. Neil Birrell, an investment chief at Premier Miton, noted it shows consumers aren’t giving up. “The budget was tough, but people’s worst fears weren’t met,” he said. Reuters

Then the latest numbers came in. The S&P Global UK Composite PMI, which tracks business activity monthly with readings above 50 indicating expansion, surged to 53.9 from 51.4—its best level since April 2024, Reuters reported. “UK businesses kicked up a gear in January,” said Chris Williamson, S&P Global’s chief business economist, even as the report noted rising inflationary pressures and softer hiring. Reuters

BoE policymaker Megan Greene stirred fresh doubts about near-term easing, expressing ongoing worries over wage growth and inflation expectations. She suggested the UK may need to roll out rate cuts more cautiously than the Federal Reserve. “I will be watching household and business inflation expectations over the next few months,” Greene said in a speech text released Friday. Reuters

Defence contractor Babcock dipped around 1.2% after announcing CEO David Lockwood will retire by the end of 2026. Harry Holt, who heads the nuclear division and is a former Rolls-Royce executive, will take over. Lockwood said, “It has been my privilege to lead Babcock, through a period that has seen the COVID pandemic.” The company also reaffirmed its confidence in hitting its fiscal 2026 growth targets. Reuters

On the mid-cap front, C&C Group tumbled 9.6% following a downgrade to its outlook. The drinks maker now forecasts adjusted operating profit for fiscal 2026 between 70 million and 73 million euros. The company cited softer sales in Ireland, disruptions from a UK systems rollout, and persistent distribution contract challenges.

Record went against the grain, pushing higher. The currency and asset manager reported assets under management hitting a new peak of $115.9 billion in Q3. Its shares climbed 3.04% to 55.64 pence in early London trading. “At $115.9bn, AUM ended another quarter at the highest level we have ever reported,” CEO Jan Witte said. London South East

Outside the UK, nerves remained frayed. Europe’s STOXX 600 slipped 0.1% by mid-morning, Reuters reported, as investors wrestled with lingering jitters from a Greenland-related trade spat — despite Washington dialing back its tariff threats. “We’ve seen a general increase in uncertainty this year,” Morningstar strategist Michael Field noted. Reuters

Yet the same data boosting UK sentiment today could backfire. Robust demand and persistent wage growth fuel inflation worries, turning “good news” into a case for higher rates — a headache for pricey sectors and households already tightening their belts on bills.

UK investors now turn to the Bank of England’s decision on Feb. 5, when it will also release its Monetary Policy Report. The Bank Rate sits at 3.75% ahead of the announcement.

Stock Market Today

  • $150M Cancer Proteomics Deal Spurs New NYSE Listing
    June 9, 2026, 9:34 AM EDT. A $150 million deal in functional proteomics, the study of protein functions and interactions critical for drug development, has led to the spin-out of a new company set to list on the New York Stock Exchange (NYSE). The company focuses on advanced cancer treatments including antibody-drug conjugates-targeted therapies combining antibodies with cell-killing agents to attack tumors precisely. Immunotherapies and targeted therapies featured in the pipeline aim to harness and guide the immune system to combat cancer effectively. Filing of the registration statement with regulators marks a key step toward public investment, enabling transparency. This development highlights the growing financial and clinical importance of proteomics in oncology and the biotech sector.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing
Previous Story

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

Brent crude price rebounds toward $65 on Trump Iran warning and Kazakhstan outage
Next Story

Brent crude price rebounds toward $65 on Trump Iran warning and Kazakhstan outage

Go toTop